Navigation Links
Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra
Date:11/17/2009

BUDAPEST, Hungary, Nov. 17 /PRNewswire/ -- Hungarian drug producer Biropharma and patent holders of its main product Avemar dispute the connection American BioSciences Inc. and its partner Mate Hidvegi are making between their recently introduced product AveUltra and Avemar, a dietary supplement being used in cancer treatment internationally for 11 years.

"AveUltra and Avemar are two different sets of compounds hence the qualities of Avemar can be attributed exclusively to Avemar, therefore all references of AveUltra to Avemar is scientifically unfounded, deceptive and abundantly unethical," Avemar's co-inventors state on Avemar's website (www.avemar.com).

Avemar is a wheat germ extract formula under patent protection designed to treat cancer patients. It is produced by Biropharma based on a definite-term contract with the holders of its patent. The product is distributed under the brand 'Ave' in the U.S.

Hidvegi, one of the patent holders, has teamed up with American BioSciences to start the U.S.-based production of AveUltra, a dietary supplement also based on wheat germ extract, but different from Avemar. According to their claims, AveUltra is developed from Avemar, however, no scientific or otherwise experimental data supports this assertion.

Several clinical studies investigated the various benefits associated with Avemar treatment and the results were published in prestigious peer reviewed medical journals. These publications cannot be used to support the claims of AveUltra.

The producers of AveUltra planned to announce the start of U.S.-based manufacturing of AveUltra at the Society of Integrative Oncology's 6th International Conference at the New York Academy of Medicine on Nov. 12-13.

Avemar's Hungarian producer Biropharma, three co-inventors and a patent holder of Avemar are disputing the steps and behavior of American BioSciences Inc. and Mate Hidvegi and planning to take all necessary steps to protect their rights in Hungary and in the United States.

According to Biropharma, the start of U.S. production of a product referring to Avemar is a series of violations of contractual rights that might make the Hungarian company go out of business.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Biropharma


'/>"/>
SOURCE Biropharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
3. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
6. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
7. Reportlinker Adds Cancer Vaccines: Measuring Market Potential
8. Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound
9. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
10. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
11. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
(Date:2/16/2017)... 16, 2017  Rhythm, a biopharmaceutical company ... that result in life-threatening metabolic disorders, today ... mezzanine round of financing with existing investors ... New Enterprise Associates, Pfizer Venture Investments, Third ... investment fund. Rhythm will use the proceeds ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
Breaking Biology News(10 mins):